Organovo Holdings Inc (NASDAQ:ONVO) showcased new preclinical data demonstrating extended survival and sustained use of its 3D bioprinted human liver tissue when fixed into unhealthy animal models. This data will be showcased at The Liver Meeting 2017 by Vaidehi Joshi of Organovo.

The details

Organovo earlier had put its 3D bioprinted human liver tissue patches into the livers of fit SCID/NOD mice, and is now exhibiting additional data from promising early trials in an established model for “A1AT”. The tissue was made of select non-parenchymal cells and human hepatocytes. Histopathologic and serum assessment of the implanted therapeutic tissue demonstrated engraftment, retention and a major degree of ailment clearing through 125-days post-implantation, a notable jump in duration from the firm’s first preclinical trials, which showed functionality through 28 days.

The data showcase a notable jump in the reported period of implanted human hepatocyte synthetic function, representing sustained presence of important human liver proteins such as A1AT and albumin in the animal bloodstream. Prominently, pathologic assessment of diseased animals getting implanted bioprinted liver tissues indicates an around 75% decline in the pathologic hallmarks of the ailment in treated animals as compared to non-treated control animals in the segment of implant.

Eric David, M.D., J.D., the Chief Strategy Officer and EVP of preclinical development at Organovo, reported that with several patients being cured for inborn errors of metabolism in the U.S., and a yearly cost per patient that surpasses $250,000 for drug therapy alone, the company continues to advance a unique therapeutic offering for direct surgical implantation.

The preclinical data continues to demonstrate robust durability and engraftment of the liver tissue and impressive early evidence of successfully impacting the ailment state in animal models. These data support sustained preclinical development of company’s 3D bio-printed liver tissue for therapeutic application.

In the last trading session, the stock price of Organovo gained more than 2% to close the day at $1.54.

Previous articleDURECT Corporation (NASDAQ:DRRX) Reports Top-line Data From The PERSIST Phase III Study Of POSIMIR®
Next articleNokia Oyj (ADR)(NYSE:NOK) Advances Cross-Selling Measures
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.